



Annual Report 2021

The central resource for the Swiss biotech industry

Impressum

Publisher:Swiss Biotech AssociationConcept and text:Sabine Bamert, Michael Altorfer, Swiss Biotech AssociationLayout:Luis Argüello, guay | corporate media designPictures:Swiss Biotech AssociationPrint:Schmid-Fehr AG
Climate-neutral print on wood-free, matt coated paper





Contents

Two decades with the Swiss Biotech Association		
Record R&D investments and 88 new members		
Swiss Biotech Ventures platform	7	
Working on offering, funding and networking	8	
Swiss Biotech Success Stories	10	
Award winners 2019	12	
Award winners 2020	13	
Award winners 2021	14	
Award winners 2022		
Genedata	16	
Etienne Jornod	18	
In the media	20	
Services and publications	21	
Financial statements 2021	22	
Development in numbers	25	
Partner network	26	
Our members	28	
About the Swiss Biotech Association	32	
Preferential business solutions for members	34	
Supporting the Swiss biotech hub: Objectives for 2022	37	

Two decades with the Swiss Biotech Association

I have had the privilege to be a member of the board of the Swiss Biotech Association for the last 20 years and president for the last nine. The association has grown and matured over this period, and I would like to take this opportunity to highlight some of the key achievements.



Dominik Escher President Swiss Biotech Association from 2013 to 2022

When I joined the board, the association had a booth at many national and international conferences. This was a great way to promote Switzerland as an attractive place for biotech and it was always a nice spot to meet at large conferences. This was a good achievement given the small team and limited resources we could afford at the time. But we wanted to do so much more for our members.

The key to achieving this was to grow the team but financial resources were very limited. We always had a tight budget and the board worked in an honorary capacity. At first, the association received federal support through projects run with the Commission for Technology & Innovation or the National Thematic Network. But these projects were limited to one or two years, making financial planning difficult. We wanted to finance the association with a longer term perspective allowing for financial stability and growth.

Today, the association is mainly financed through member fees. Membership fees allowed us to grow the management team from 0.6 full time employees to 3.5 today. Growing the team meant that we could start to expand our activities and by doing so, we enhanced the relevance of the Swiss Biotech Association to the industry, creating a virtuous circle of service and growth.

We launched the Swiss Biotech Day to complement our annual general meeting. Our aim was to bring together Swiss biotech entrepreneurs and to foster networking in our industry. In 2021, we welcomed close to 900 participants, not only from biotech companies but also the pharma industry and venture capital firms, representing 27 different countries. Over 20 years this event has grown to become the largest biotech event in Switzerland.



Alongside these activities we started to add member benefits: corporate promotion through the association, a job portal, publishing news from our members, negotiating discounts at many conferences and better prices for employee benefit solutions and insurance, offering discounts for lab and other supplies, as well as discounted access to publications.

We were also lobbying and working to improve the framework conditions for Swiss biotech companies. Back in 2016, we were pushing back against the new taxation rules for start-ups. More recently we have been campaigning against the initiative to ban animal testing and clinical trials.

Another major new feature has been the launch of success stories to promote biotech and make our industry more visible. Every year, several case studies are selected to show the public how biotech companies contribute to helping patients and making a valuable and significant contribution to the Swiss economy.

All of this work over the last 20 years has supported the continued growth and relevance of the association. So much so that by the end of last year we had achieved a new record of 364 members in the Swiss Biotech Association.

Looking back on this 20 year journey, I would like to thank all of my colleagues for the many enjoyable meetings and interactions. The association still has a lot to do. Issues - such as the decreasing numbers of early clinical trials in Switzerland, funding gaps and a limited talent pool - mean that the association and its work remain critically relevant to the ongoing success of the industry.

In the future, I look forward to supporting Swiss biotech companies through direct

engagement and I wish the board and the management team lots of success in directing the Swiss Biotech Association through the next 20 years.

I am sure Switzerland will remain one of the most successful countries for our industry.

Sincerely yours,

hnha

Dominik Escher President Swiss Biotech Association

Record R&D investments and 88 new members



The Covid pandemic continued to be a dominant factor in 2021, and Switzerland was again one of the countries that contributed innovative and valuable solutions. While the development and manufacture of vaccines and diagnostics were the focus in 2020, in 2021 Humabs Biomed/Vir Biotechnology and Molecular Partners succeeded in developing effective Covid-specific therapeutics.

At the end of 2020, we had cautioned that the Covid pandemic could jeopardize the development of the Swiss biotech pipeline and innovation power. While some delays were inevitable, there was no major slowdown in terms of financing and R&D investments. In fact, 2021 turned out to be another strong year with a capital influx of more than CHF 3.3 billion and R&D record investments exceeding CHF 2.5 billion.

Overall, the Swiss biotech industry remained remarkably robust:

- Employment in R&D biotech companies increased by almost 10% in 2021
- Pharma and biotech exports also rose by about 10% to around CHF 110 billion, contributing roughly 42% to the Swiss exports
- Anaveon and Numab Therapeutics proved that the private financing market in Switzerland is strong and supports large financing rounds exceeding CHF 100 million
- The very successful IPOs of SOPHiA GENETICS and VectivBio, which together raised close to CHF 400 million, also proved that public market access was alive and well

In 2020, we could not organize the Swiss Biotech Day due to the constraints imposed by the Covid pandemic. But in September 2021 we found back to the established live format. It was a roaring success with a record attendance of more than 850 participants. Despite the pandemic, about 30 percent of attendees came from abroad, representing some 27 nations.

In 2021, 88 new members joined the Swiss Biotech Association, bringing total membership to 364 companies, the largest in the history of the association. This strong and increased support helps us to deliver on our mission with far greater impact:

- Launching the Swiss Biotech Ventures platform to match biotech ventures, investors, and pharma partners
- Expanding the partner network of the SBA Academy platform
- Maintaining an effective networking presence through the online 'Swiss Pavilions' at BIO US and BIO Europe, and through free access to the BiotechGate Digital Partnering for our members
- Securing membership in the health policy commission of economiesuisse
- Granting Swiss Biotech Success
 Stories Awards to Bachem, Basilea, EsbaTech, Lonza, and Novimmune

Our objectives for 2022 are outlined on page 37 onwards. Please reach out to board members and the management team (see p. 32) with your feedback, and support us in providing a strong voice for the Swiss biotech ecosystem.


Yours faithfully,

Michael Altorfer CEO



Swiss Biotech Ventures platform

In 2021, the unique Swiss Biotech Ventures platform was successfully launched at the Swiss Biotech Day, facilitating the funding, partnering, and licensing between biotech companies, investors, and pharma companies. Visit ventures.swissbiotech. org to profile your venture, list yourself as an investor or industry partner, and to find attractive partnering and investment opportunities.





Working on offering, funding and networking

The Covid pandemic also dominated 2021. However, the Swiss Biotech Association continued to provide support for its members and the Swiss biotech industry.

Launch of the unique Swiss Biotech Ventures platform: Matching biotech investment opportunities with investors at ventures.swissbiotech.org Swiss Biotech Association becomes a **member** of the health policy commission of

economiesuisse

Successful comeback of the Swiss Biotech Day with 850 guests enjoying networking opportunities at Switzerland's leading biotech conference and the industry event of the year

Publication of the Swiss Biotech Report 2021 demonstrating the exceptional performance of the Swiss biotech industry and a strong fundraising of CHF 3.4 billion





Numerous association presentations and partnering events throughout the year, including presence at the Ilmac in Basel and panel participation at the Sachs investor conference

Media release and coordinated global approach to oppose intellectual property waiver


Launch of the leading Swiss Biotech Directory 2021 with more than 1,000 companies

Expanding our presence to Basel with a representation at the Basel area chamber of commerce



Conducting interviews with national and international media to highlight the strong contribution of Switzerland to mitigate the impact of the Covid pandemic

Presenting Swiss biotechs virtually in the Swiss Pavilion with Switzerland Global Enterprise at BIO International and Europe conventions



Webinar on new funding

schemes stimulating sciencebased innovation on the impulse program by Innosuisse and the subordinated loan guarantee program by Basel-Stadt

Cooperation with Euresearch

to communicate possibilities for Swiss participation in Horizon Europe

Supporting efforts to strengthen and position Switzerland

as a manufacturing country and a leading center in antibiotic research

Regular Swiss Biotech CEO

updates, the annual meeting, and biotech CEO networking events with investors and multi-national pharma companies



Zürich, May 12, 2021

Weakening patent protection for COVID-19 vaccines does not help to accelerate vaccine production but endangers science-based innovation

The proposal to the WTO, to weaken the patient protection for COVID-19 vaccines, incorrectly portrays IP as rapid access to vaccines. While this initiative does not address the crisis in an effective es send an extremely dangerous signal to innovators and investors alike. A robust and reliable is indispensable for science-based innovation. What sounds good at first glance is dangerous

Exposing the negative impact of the people's initiative to ban clinical trials and animal testing by communicating to the public and the network



SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

Swiss Biotech Success Stories demonstrate the power and potential of the industry

The Swiss Biotech Success Stories Awards recognize valuable accomplishments and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The awards are presented each year at the Swiss Biotech Day and reflect the diversity and achievements of this innovative sector.



Switzerland is one of the world's leading biotech hubs and attracts many foreign companies, specialists and investors. It provides over 50,000 jobs and, together the biotech and pharmaceutical industries, account for more than 40% of Swiss exports.

To make the industry's impact more visible, the Swiss Biotech Success Stories initiative was launched in 2018. Selected success stories are showcased to illustrate how Swiss biotech companies help patients, improve health care worldwide, and make a valuable and significant contribution to the Swiss and global economy.

Laureates are individuals or groups who have earned extraordinary merits. Success is broadly defined as scientific, translational, medical or commercial, together with other aspects that have a positive impact on the biotech and life science industry and society in Switzerland.

"It is essential to share with the public the importance and success factors of biotech companies and ensure that decision-makers understand what it takes for the industry to develop and remain competitive," says Michael Altorfer, CEO of the Swiss Biotech Association. "Young talent should be inspired and motivated to take a closer look at the great variety of career profiles in biotech."

12 success categories

- Completed achievement with lasting impact
- Scientific breakthrough
- New technology
- Strong impact on society
- Product approval and sustainable revenues
- Important IP, innovative deal-making, acquisition
- Involvement of one or more Swiss citizens
- Swiss-based company / institution
- Creation of jobs in Switzerland
- Other aspect with a direct link to Switzerland
- Enabler for the biotech industry
- Swissness: Think global, made in Switzerland







Luca Bolliger President of the jury Vice President Swiss Biotech Association



Patrick Aebischer Entrepreneur Former President of EPFL



Stefanie Flückiger-Mangual Chief Executive Officer and Co-Founder Tolremo



Gabrielle Gache President Swiss Healthcare Licensing Group



Ulrich Geilinger Co-Founder and Senior Partner, Head of Private Equity HBM Partners



Seraina Gross Business journalist Handelszeitung



Daniela Marino Chief Executive Officer and Co-Founder Cutiss



Jürg Zürcher Expert and EY senior advisor in the biotech field



Thomas Staffelbach Secretary of the jury TS Kommunikation

A big thank you to our partners

Sponsors

SWITZERLAND GLOBAL ENTERPRISE



The Swiss Biotech Success Stories Awards are also supported by



SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

Award winners 2019

Biogen.

Headquartered in Zug, Biogen has been a key stimulus and model for the biotech industry. Its best-selling drug for multiple sclerosis or its Alzheimer's candidate, as well as the new production facilities in Luterbach, creating 600 new jobs, are proof of Biogen's success.

GLYCART

The Schlieren-based company is an integral part of Roche Pharmaceutical Research and Early Development since 2005, and a pioneer in antibody engineering in cancer immunotherapy. Its antibody glycosylation technology increases immune-mediated cancer cell killing and builds the basis for improved cancer medicines.



SELE><IS[®]

Fully integrated into GlaxoSmithKline since 2013, Okairos from Basel developed innovative T-cell based vaccines for major infectious diseases such as malaria, hepatitis C, HIV, and Ebola. Its novel replication-incompetent adenovirus vectors could enable the development of important new vaccines and offer immunizations against illnesses that lack vaccines.


The advanced technologies in protein expression by Selexis allow biotech and pharmaceutical companies a rapid, stable, and cost-effective solution for the production of recombinant proteins. Almost one hundred drug candidates in clinical development and three commercial products utilize the technologies of the Plan-les-Ouates-based company.

▼ VFOR FRESENULY MEDICAL CARE ▼
This transformational joint venture provides Vifor Pharma direct access to dialysis patients, facilitating the product distribution and recruitment for clinical development. It transformed the company from Glattbrugg rapidly into a global nephrology corporation. Such vertical integration is a role model for the convergence of different life science sectors.





Award winners 2020



SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements

Award winners 2021

BACHEM

Bachem is a leading manufacturer of peptides and oligonucleotides. The company has grown over 50% in the last five years and now offers more than 5,500 different biologically activepeptides amino acid derivatives and oligonucleotides. Its investment plans call for the investment of over USD 400M to continue to pursue its growth strategy.

(basilea)

Basilea Pharmaceutica is a leader in targeted oncology small molecules, novel antibiotics and antifungals. Since its listing in 2004 (SIX: BSLN), Basilea has launched two anti-infective treatments: Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole), an antibiotic for severe hospital bacterial infections.



ESBATech, now a Novartis company, is recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications. The most advanced product from the ESBATech platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.

Lonza

Lonza is a global leader in contract development and manufacturing services with strong R&D capabilities and world-class facilities across five continents. In 2020, Lonza supported more than 820 pre-clinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced 230 billion capsules.

novimmune တိ

Founded by the renowned immunologist, Professor Bernard Mach MD PhD, privately-owned Novimmune is a leading light in the discovery and development of fully-human, antibody-based drugs used to fight autoimmune and inflammatory diseases and cancer.





Open up your network

To ensure that the Swiss Biotech Success Stories will be visible around the globe in many locations, media and events, help us with your network and distribution power.



Let us know if you have contacts in your network who could benefit from the insight into Swiss Biotech Success Stories, and are curious to learn more about the stunning accomplishments of entrepreneurs in this competitive industry.

Interested parties could be: Your customers, suppliers, partners, a journalist, an investor, your company's communication unit, your follower base on social media, your favorite politician, an event platform dedicated to life science, your rotary club colleagues or any other possibility, that could help to promote these success stories. Share with us your suggestions for spreading the word by email to success@swissbiotech.org or use the QR code to get to our online form.



SWISS BIOTECH SUCCESS STORIES

Award winner 2022





Genedata is the globally leading provider of enterprise software for digitalizing data-rich and complex biopharmaceutical R&D processes. Incorporating extensive biopharma R&D domain knowledge, Genedata software helps biopharmaceutical organizations to streamline work-flows, increase research automation, improve experimental data quality, and maximize the ROI in R&D expenditure, which results in innovative biotherapeutics reaching patients faster.

Founded in 1997 by Othmar Pfannes, Ph.D., Genedata is privately owned and headquartered in Basel, Switzerland. Organic growth and a strong commitment to its employees are the cornerstones of Genedata's 25-year history.

With more than 300 employees and offices strategically located throughout Europe, the USA, and Asia, Genedata works closely with global industry leaders to help them deliver innovative biotherapeutics, vaccines, and cell & gene therapies to patients more efficiently.

Today, over 200 R&D institutions rely on the Genedata Biopharma Platform, including all top-25 biopharma companies worldwide.

Knowledge



- Experienced Global Market Leader Established in 1997 & privately owned with +300 people in Basel, Boston, London, Munich, San Francisco, Singapore, and Tokyo
- Innovative Enterprise Platform Scalable and open built-for-purpose E2E platform; streamlines and automates data-rich & complex R&D processes out-of-the-box
- Unique Domain Expertise In-depth biopharma R&D knowledge ensures delivery of integrated solutions aligned with industry best practices
- Marquee Customer Base Increasing R&D efficiency and driving innovation with biopharma R&D leaders around the globe via long-term relationships
- Successful Partnerships Worldwide Flexible and collaborative business model accelerates digital transformation to maximize ROI

SWISS BIOTECH

Success Categories

- ★ Completed achievement with lasting impact
- ★ New technology
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizen

Core Team



Othmar Pfannes Ph.D. CEO & Founder



Hans Peter Fischer Ph.D. Director



Peter Haberl Ph.D. Director



Stephan Heyse Ph.D. Director



Kurt Zingler Ph.D. Director

Genedata Biopharma Platform

The Genedata Biopharma Platform is the market leading solution that digitalizes biopharmaceutical R&D processes and enables an R&D revolution driven by artificial intelligence approaches to generate the precision medicines of the future.



Enables Innovation Through Better Insights

Accelerates Workflows Through Al-driven Automation

Improves Probability of Success Through Better Data Quality

Increases Clinical Trial Efficiency Through Better Integration

- ★ Swiss based company
- Creation of jobs in Switzerland
- ★ Other aspects with a direct link to Switzerland
- ★ Swissness: Think global, made in Switzerland

Organized by
Swiss Biotech
Association

SWISS BIOTECH SUCCESS STORIES Award winner 2022



Etienne Jornod

Etienne Jornod spent his entire career at Vifor-Galenica Group where he was Executive Chairman until early 2020.

Since October 2020, he is Executive Chairman and Co-Owner of OM Pharma.



Trust is the basis of any collaboration, therefore of any project Performance & Deliver what we promise creates trust To succeed we must be honest, transparent and love people

VIFOR Revolutionizing Iron Sucrose PHARMA

The development of an injectable medication to treat iron deficiency anemia in patients with chronic kidney disease marked the beginning of Etienne Jornod's entrepreneurial success at Vifor Pharma.

Developing Ferric Carboxymaltose

This iron success was followed by the development of a novel iron complex, enabling controlled delivery of iron to target tissues throughout the body.

VIFOR FRESENIUS MEDICAL CARE **RENAL PHARMA**

This Joint Venture with Fresenius-FMC, in which Etienne Jornod was extensively involved, resulted in the successful launch of Mircera® in the US in partnership with Roche, and has attracted new licensed products in the field of dialysis: Rayaldee®, Tavneos®, Kapruvia®, Vadadustat®.

Success Categories

- ★ Completed achievement with lasting impact
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizen
- Swiss-based company/institution

SWISS **BIOTECH**

Transitioning to OM Pharma



When Etienne Jornod decided to leave, Vifor-Galenica Group has been able to deliver 25 consecutive times a double-digit growth in net profit and increase the value of its share from CHF 3.40 to CHF 185.25, with a total value increasing from MCHF 220 to MCHF 1,200 from 1995 to 2019.

During his tenure, the company has improved the lives of millions of patients and created thousands of jobs.

Who is OM Pharma

OM Pharma is a global biopharmaceutical company, leader in the prevention of recurrent respiratory and urinary tract infections. In October 2020, Etienne Jornod bought it from Vifor Pharma with his friends.



Its leading products Broncho-Vaxom® and Uro-Vaxom® are bacterial lysates, composed respectively of 21 and 18 pathogen bacterial strains. Manufactured in Geneva, they are distributed in more than 100 countries across the world, via an established, international network of partners.



OM Pharma employs around 450 people globally and has a strong presence in Switzerland, with 350 people in Geneva (Global headquarters & biotech center).

The New OM Pharma's Vision

With the New OM Pharma project, Etienne Jornod aims to create a very innovative biopharmaceutical company based on the unique bacterial lysate expertise developed over decades by OM Pharma.

Encompassing seven projects, the goal of improving patients' lives is central to the development of new medicines for asthma, atopic dermatitis, wheezing and other diseases of the respiratory and urinary systems.

C III Knowledge & Research

High levels of biotech knowledge and experienced teams with substantial know-how in the manufacturing of immunomodulators based on active bacteria.

Innovative scientific research aiming at extending the use of bacterial lysates for the prevention and treatment of a wide range of immuno-inflammatory diseases, as well as development of new chemical entities.


- ★ Creation of jobs in Switzerland
- ★ Other aspect with a direct link to Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland

Organized by
Swiss Biotech
Association



In the media


Key articles and interviews in leading Swiss media supported our goal in making sure that the biotech industry got heard in the public.





Services and publications

One of the Swiss Biotech Association's goals is to enhance the image of the biotechnology industry in Switzerland and abroad, and position it as an important value-adding economic pillar. Besides the Swiss Biotech Success Stories (see p. 10-19), our publications and digital services support the association's drive to expand its impact and strengthen its role as the central resource for the Swiss biotech industry.



Income statement

	2021		2020	
In CHF	Expenses	Income	Expenses	Income
Membership fees		729,500		610,500
National projects 1		481,231		13,200
Swiss Biotech Success Stories		0		10,000
Swiss Biotech Report		52,000		48,000
Swiss Biotech Directory		22,910		19,201
Increase/decrease bad debt provision		0		-4,700
Total income		1,285,641		696,201
Fees to other associations	26,365		20,676	
International projects	17,037		9,945	
National projects 1	509,735		45,984	
Swiss Biotech Success Stories	13,717		22,316	
Increase/decrease tied capital "Swiss Biotech Success Stories"	-5,000		-15,000	
Swiss Biotech Sounding Board	5,253		9,102	
Increase/decrease tied capital "Swiss Biotech Sounding Board"	-5,000		-15,000	
Swiss Biotech Report	60,946		50,894	
Swiss Biotech Directory	31,398		41,626	
Website & community platform	99,553		47,269	
Association activities expense	754,004		217,812	
Management fees ²	317,912		295,129	
Accounting & member support	122,468		104,185	
Office rent & administration	26,232		20,534	
Consulting	13,150		24,604	
Public relations	48,399		51,908	
Other operating expenses	528,160		496,360	
Financial income result		-3,914		-299
Income from previous reporting periods		16,501		-8,082
Tax expenses	378		500	
Net proft/loss for the year		15,686		-26,852

¹ In 2020 we had to cancel the Swiss Biotech Day due to the Covid-19 pandemic. While costs were incurred to plan and prepare, no income was generated

² Management fees related to events and promotional products are directly booked to the respective project



Balance sheet

	Balance She	et 31.12.2021	Balance Shee	et 31.12.2020
In CHF	Assets	Liabilities	Assets	Liabilities
Assets				
Cash and cash equivalents	233,314		246,800	
Accounts receivable	22,019		25,885	
Accrued income & prepaid expenses	16,590		11,765	
Total assets	271,923		284,451	
Liabilities				
Accounts payable		36,064		49,967
Accrued expenses & deferred income		65,360		69,671
Association equity		131,239		131,239
Tied capital for SBA Success Stories		10,000		15,000
Tied capital for SBA Sounding Board		10,000		15,000
Retained earnings		3,575		30,426
Net result of the year		15,686		-26,852
Total liabilities		271,923		284,451

Auditor's report



BDO Ltd, a limited company under Swiss law, incorporated in Zurich, forms part of the international BDO Network of independent member firms.



Development in numbers

In 2021, 88 members joined the Swiss Biotech Association, a new record. Our website, newsletters and mailings provide an up-to-date and comprehensive picture of what is happening in the Swiss biotech industry. As in the past years, the number of newsletter subscribers and website visitors increased again.



Partner network

National and international partnerships of the Swiss Biotech Association help us leverage our impact. They strengthen our voice and enable us to provide Swiss biotech stakeholders with privileged information and networking opportunities.

Optimizing framework conditions for Swiss biotech companies

- ▶ economiesuisse
- EuropaBio
- International Council of Biotech Associations
- Interpharma
- scienceindustries
- Swiss Coordination Committee for Biotechnology

Fostering international collaborations & trade

- BIO Deutschland
- Biotechnology Innovation Association (UK)
- SwedenBIO
- Europe-Taiwan Biotech Association
- Italian Trade Agency
- Japan Bioindustry Association
- Korea Trade-Investment Promotion Agency
- SwedenBIO
- Swiss Business Hubs
- swissnex

Promoting Switzerland's competitive advantages

- Agire
- Basel Area Business & Innovation
- Basel Chamber of Commerce
- BioAlps
- Canton of Vaud Chamber of Commerce and Industry
- Farma Industria Ticino
- Greater Geneva Bern Area
- Greater Zurich Area
- Life Sciences Cluster Basel
- St. Gallen Bodensee Area
- Switzerland Global Enterprise

Connections to investors & non-dilutive funding opportunities

- Euresearch
- Innosuisse
- Sachs Associates
- SECA
- SIX
- Swiss Healthcare Startups
- Venture Kick

Swiss Biotech Association Academy

- Basel Area Business & Innovation
- CTC Resourcing Solutions
- DIA
- European Center of Pharmaceutical Medicine
- Euresearch
- EPFL
- Henri B. Meier Unternehmensschule Unversität St. Gallen
- Loroch
- siteminsel
- Swiss HLG
- Swiss Institute of Bioinformatics
- Università della Svizzera italiana
- Universität Bern
- University of Applied Sciences and Arts Northwestern Switzerland
- Venturelab

Preferential business solutions

- BioCentury (info, analysis and data for biotechs)
- Helvetia (business insurance)
- ProcEurope European Life Sciences Purchasing Consortium (lab supplies)
- LubioScience (research reagents & lab supplies)
- Springer Nature (scientific and technical publisher)
- Swiss Life (pension fund)
- More than 100 co-promotion partners organizing events & conventions around the globe

Swiss Biotech Success Stories

- EY (silver sponsor)
- Switzerland Global Enterprise (silver sponsor)
- Gebert R
 üf Stiftung, Innotio, Basel-Stadt, TS Kommunikation (supporters)

Swiss Biotech Report

- biotechnet
- EY EY
- scienceindustries
- SIX
- Swiss Academy of Engineering Sciences
- Swiss Federal Institute of Intellectual Property
- Swiss National Science Foundation
- Switzerland Global Enterprise

Links to specialized stakeholder groups

- biotechnet Switzerland (academia)
- LS² Life Sciences Switzerland (life sciences)
- SimplyScience (young talent)
- Swiss HLG (business development)

List of members, December 2021



88 members that have joined the association in 2021 are shown in red

4G Clinical B.V.

abcDNA GmbH ABCDx SA Abologix Sàrl AC Bioscience SA AC Immune SA ACM Biosciences AG Acthera Therapeutics AG Activen SA ADC Therapeutics SA Addex Therapeutics Ltd Adiposs Sarl Adolf Kühner AG Advitech Advisory and Technologies S.A. Agidens AG Alentis Therapeutics AG Alithea Genomics SA Alphastrat GmbH Altasciences AlveoliX AG Amal Therapeutics SA AMYRA Biotech AG AnaPath Services GmbH Anaveon AG Aniarium Biosciences AG anteris Helvetia AG Aptissen SA Araris Biotech AG ARTIDIS AG ASC Oncology Schweiz AG Asceneuron SA Assystem Care Switzerland SA Athebio AG Auregen Biotherapeutics SA Avance Basel GmbH Avrion Therapeutics AG Axon Lab AG Baccinex SA Bachem AG BakerHicks AG Baliopharm AG Basilea Pharmaceutica Ltd. BC Platforms AG

Becton Dickinson AG BERNINA BioInvest AG BIDECO AG BioConcept AG

BioCopy AG

Bioengineering AG Biogen International GmbH BioLingus AG Biolytix AG BioMedPartners AG Biopôle SA Bio-Rad Laboratories AG Biosynth Carbosynth AG Bio-Technopark Schlieren-Zürich BioVersys AG BISC Global GmbH blsc - bihlmann life science communication Bright Peak Therapeutics AG Bromatech (Suisse) SA Bucher Biotec AG Büchi AG Bühlmann Laboratories AG Cabinet Privé de Conseils s.a. (CPC) Calypso Biotech SA Cancer Research and Biotechnology AG Canlion AG CanVirex AG Carbogen Amcis AG CarthaGenetics Suisse Sarl

Catalent Pharma Solutions GmbH

Catalyze Switzerland GmbH C-CIT Sensors AG CDR-Life AG CEBIS International Celerion Switzerland AG Cellestia Biotech AG Cell Receptor SA

cellvie AG

Celonic AG

Cerbios-Pharma SA Cerdia International GmbH certus molecular diagnostics ag Chemgineering Switzerland AG Cilatus Biopharma Consulting AG CimArk SA

Cimeio Therapeutics AG

CIS Pharma AG Clemedi AG Clinipace AG Consultants in Science Sarl **CORETAG Holding AG Coulter Partners** Covance Central Laboratory Services Sàrl CRB Group GmbH Creoptix AG **CROss Research SA** CSEM CSL Behring AG **CTC Resourcing Solutions** Culture Collection of Switzerland AG Curatis AG CUTISS AG Cytosurge AG Cyxone Switzerland AG D36.ch Sarl Dao Tun GmbH Diaxxo AG Debiopharm International SA Deep Breath Intelligence AG deepCDR Biologics AG **DINAQOR AG** Dr. Remus Muresan Legal Services DrM, Dr. Müller

ECS-Progastrin LAB SA

EffRx Pharmaceuticals S.A. Elthera AG **Emergent BioSolutions** EraCal Therapeutics Ltd Eurofins BioPharma Product Testing Switzerland AG Eurofins Genomics GmbH Evitria AG ExcellGene SA ExpertInova AG Fluidic Analytics Ltd Future Health Pharma GmbH G&L Scientific (Schweiz) GmbH Gain Therapeutics SA GALSER SA GBiotech Sàrl GE Healthcare AG Genedata AG GeNeuro SA Geneva Biotech Center (GBC) SA Genexa AG Genkvotex SA GenSearch Switzerland GlycoFra AG GMT Fine Chemicals SA Gnubiotics Sciences SA HBM Partners AG headcount AG Health Advances GmbH Helsinn Healthcare SA HEMEX AG HEXAGONFAB LIMITED HGF GmbH Homburger AG Humabs BioMed AG Hyperbolic Holdings GmbH IBR Inc., Institute for Biopharmaceutical Research Ichnos Sciences SA ICON Clinical Research (Switzerland) GmbH Idorsia Pharmaceuticals Ltd. IF Life Science Engineering AG ImmunOs Therapeutics AG InCenhalo AG Incyte Biosciences International Sàrl Infors AG InnoMedica Holding AG Innovative Sensor Technology IST AG INOFEA AG Inositec AG InsideReg Sarl InSphero AG Integra Biosciences AG InterAx Biotech AG Inthera Bioscience AG IOnctura SA Janssen-Cilag AG

Jenal & Partners Biosafety Consulting JFG Life Sciences Stiftung JMP Software, SAS Institute GmbH

Kinarus AG

KPMG AG Labatec Pharma SA Laevoroc Oncology AG LAGOSTA SA

LaForce Business Solutions Sagl LATAM Pharma Innovative Ventures AG

Laves-Arzneimittel GmbH LeadXpro AG Life Sciences Executive Search LLC Light Chain Bioscience - NovImmune SA LimmaTech Biologics AG Limula SA Linkster Therapeutics AG Lino Biotech AG Lonza AG Loroch CTLS

LS Instruments LubioScience GmbH Lunaphore Technologies SA LYO-X GmbH Malcisho AG Matterhorn Biosciences AG

Maxia Strategies GmbH

MaxWell Biosystems AG MD Biosciences GmbH Med Discovery SA MEDExpansion Sarl Medical Trials Analysis Swiss SA Memo Therapeutics AG Merz/Anteis SA MetrioPharm AG Micro-Sphere S.A. Microsynth AG Molecular Partners AG Monte Rosa Therapeutics AG MUVON Therapeutics AG **MV BioTherapeutics SA**

Mymetics SA Nagi Bioscience SA NBE-Therapeutics AG

NDA Regulatory Service Switzerland GmbH Nemis Technologies AG NeoGenomics Laboratories Europe SA Neovii Pharmaceuticals AG Neurimmune AG NextImmune AG Nice & Green SA Nodes Advisors AG Noema Pharma AG NovaGo Therapeutics AG Novaremed AG Novartis Pharma AG Novigenix SA Novochizol SA Numab Therapeutics AG ObsEva SA Occident Group AG Oculis SA Oculox Technologies SA OM Pharma I td

OMNI Life Science GmbH

Omva International AG

Onelife SA **Onward Therapeutics SA**

oprandi & partner romandie sa Orion Biotechnology Switzerland P&G MedChem AG Pall (Schweiz) GmbH PAREXEL International (CH) AG Peleven AG Perseo pharma AG Phargentis SA Pharma Globe AG PharmaBiome AG Pharma-Consulting ENABLE PharmNDev Experts SA

Pharvaris GmbH

Philip Morris International Philochem AG Phoenixus AG plusbiome AG

PLX Healthcare Services (Schweiz) AG Polyneuron Pharmaceuticals AG PolyPeptide Group AG

Polyphor AG Preclin Biosystems AG PreComb Therapeutics AG Promega AG ProteoMediX AG PSI CRO AG Pureos Bioventures QBDC GmbH Quartz Bio SA

Quercis Pharma AG

Quotient Suisse SA RADAR RP Sàrl Recordati AG Redbiotec AG Regen Lab SA Rejuveron Life Sciences AG Remap Consulting GmbH Repertoire Immune Medicines (Switzerland) AG

Resea Biotec GmbH

Resistell AG Rhizen Pharmaceuticals AG Ridgeline Discovery SA Roche Glycart AG Rockwell Automation Switzerland Rowestil Consulting GmbH Saiba AG

SAKK

Santhera Pharmaceuticals (Switzerland) AG Santersus AG Sartorius Stedim Switzerland AG Saverna Therapeutics AG

Scailvte AG Schmidt Versicherungs Treuhand AG SeaGen International GmbH Securecell AG Selexis S A Senn Resources AG Sferalp SA SFL Pharma GmbH SGS Analytics Switzerland AG SGS Société Générale de Surveillance Shimadzu Schweiz GmbH SICPA SA

Sintetica SA

Sirius Scientific Consulting AG Socorex Isba SA Sophia Genetics SA SpacePharma SA SPINOFRIN SA

STALICI A SA

Stobbe Pharma GmbH Strategy Consulting Dr. Rudolf K.Sprüngli SunRegen Healthcare AG Superlab Suisse AG swati AG Swiss Biotech Center SA SWISSAVANS AG

SwissBiotechSolutions

Swissfillon AG SwisSolution Human Capital AG Switzerland Global Enterprise Swizzard Pharma AG SynDermix AG

Syneos Health Switzerland GmbH

Synple Chem AG T3 Pharmaceuticals AG Talentmark Life Sciences Consulting GmbH Talisto GmbH

TargImmune Therapeutics AG ten23 Health AG

The RSA Group therainnova AG

Thermo Fisher Scientific Life Technologies Tigermed Swiss AG Tillotts Pharma AG

Tissuelabs Saul

tiventa AG TOI REMO therapeutics AG Toolpoint for Lab Science Topadur Pharma AG UCB Pharma AG/UCB Farchim SA Vaderis Therapeutics AG

valuationLAB AG VectivBio AG

Vector BioPharma AG

Venture Valuation Versameb AG Versantis AG Vifor Pharma Management Ltd. Viopas Venture Consulting GmbH VirdisGroup Sàrl Virometix AG VISCHER AG

Voisin Consulting Life Sciences VTU Engineering Schweiz AG

Walder Wyss

Wellmera AG Werthenstein BioPharma GmbH WuXi AppTec Wyss Zurich Xcenda Switzerland GmbH YAFO Capital (Shanghai) Co. Ltd Zenith Technologies Zeta CH AG



We enhance the visibility of biotech companies

These members profit from a cost-effective and easy-to-do marketing opportunity. For one year their logos feature on our communication tools. These include the Swiss Biotech Association exhibition booth at renowned conferences, publications, and presentations about the Swiss biotech industry for stakeholders, talents, partners, media, investors, and one-on-one meetings.















HEALTH ADVANCES





Maxia















PHARVARis

PSI















SFL PHARMA



Swiss Biotech Association board and management

The board



Dominik Escher President Executive Chairman CDR-Life



Bettina Ernst Vice President CEO Preclin Biosystems



Patrick Amstutz Vice President CEO Molecular Partners



Ulf Grawunder Vice President Managing Partner Viopas Venture Consulting



Luca Bolliger Vice President CEO abcDNA



Martin Howald Vice President Honorary Member CEO BioConcept



Jurgi Camblong Vice President CEO SOPHIA GENETICS



Filippo Riva Vice President CEO Humabs Biomed

The management team



Michael Altorfer CEO



Patrick Imwinkelried Accounting Wespi & Partner



Sabine Bamert Head of Communications



Carsten Laue Funding & community platform



Heike Bihlmann Liaison Basel Area, member support, special projects



Fabio Napoletano Head Business Development Liaison Bern & Ticino



Marta Gehring Biotech Insight Meetings



Aditya Yellepeddi Liaison Romandie



The Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech[™].



Our Mission

The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.

Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.

To this end, the Swiss Biotech Association is dedicated to supporting Swiss biotech companies through the following:

Developing favorable and competitive framework conditions

- Creating awareness of the biotech industry's needs and interests with policy makers
- Advocating a competitive tax system alongside lean and pragmatic regulations
- Fostering life science education, technology transfer and intellectual property

Attracting talent, know-how and financial resources to drive innovation and growth

 Promoting and facilitating access to funding opportunities

- Connecting investors and attractive biotech investment opportunities
- Facilitating access to national and international talent

Fostering networking through strategic, national and international partnerships

- Connecting industry stakeholders and life science clusters
- Organizing and co-promoting national and international life science events
- Providing access to privileged information through industry platforms and working groups

Promoting the accomplishments of the Swiss biotech industry

- Disseminating the value-creation of Swiss biotech companies
- Visualizing the diversity and competitiveness of Swiss biotech companies
- Presenting innovative products and technologies and their contribution to quality of life



Preferential business solutions for our members

In collaboration with business solution partners, the Swiss Biotech Association creates value for its members by leveraging their combined purchasing power, resulting in significant cost savings for running their business. Should you have requirements for additional business solution partners, or like to become one, please let us know (see team on p. 32).

Swiss Life's pension fund

SWISS BIOTECH 's Life

With the Swiss Biotech Association employee benefits solution, our members join forces and benefit from significantly more attractive risk and cost contributions for occupational benefits with Swiss Life.



Helvetia's business insurance

Our members can cover their business risks with Helvetia's individual and modular options. Their 8 in 1 discounted offer includes insurance for movable property, buildings and buildings liability, technical, marine, as well as assistance, legal protection, public and professional liability.



LubioScience's portfolio

Our members benefit from special discounts on LubioScience's entire portfolio of 4+ million antibodies, proteins, assay kits and lab reagents, and free shipping. They also can access their procurement services and custom services solutions.







ProcEurope's laboratory supplies

Our members benefit from significant discounts on laboratory supplies and equipment, e.g. from Fisher Scientific, by the European Life Sciences Purchasing Consortium.





BioCentury's market research

A complimentary test access to BioCentury's Intelligence platform, as well as discount on the subscription helps our members' executives and investors solve business-critical decisions and to a better positioning by independent deep-dive analysis, high-quality data, and business intelligence on a global scale.



A trusted and essential partner to the biopharmaceutical industry, providing 27 years of in-depth research, analysis and data on innovation and excellence – from biology to the patient.



Springer Nature's leading publications

The world's leading scientific and technical publisher Springer Nature offers our members subscription discounts between 25% and 50% for some of their most exciting products.





Springer Nature is excited to be part of Swiss Biotech Association. We're celebrating our partnership by offering introductory rates of 25-50% off to new subscribers for access to our most relevant content.

Your Contact at Springer Nature Béatrice Bourgogne



Save the date!

SWISS BIOTECH DAY 2023

April 24-25, 2023 Congress Center Basel

What you can expect:

C Swiss Biotech Association

- Meet 850+ senior experts from the life science industry
- > 50+ exhibitors from across Europe
- > Delegations from various regions
- > Swiss Biotech Success Stories Awards
- Innovative biotech start-ups and medium-sized biotech companies
- > Thematically focused panel discussions
- > Pre-scheduled one-to-one partnering meetings
- > General Assembly of the Swiss Biotech Association

Sign in on our website at www.swissbiotechday.ch and stay updated about any news.

Media partners:








Organized by:





Supporting the Swiss biotech hub - Objectives for 2022

The 2022 objectives of the Swiss Biotech Association link to one of the four mission pillars (see p. 33) or enhance the financial flexibility and operational effectiveness of the association.



Favorable frameworks

While Switzerland still offers one of the most attractive framework conditions for sciencebased innovators, the international conditions are becoming increasingly challenging as many nations turn to national and protective measures. Such measures hinder international cooperation and complicate joint R&D. As it becomes more difficult to share results, and additional framework hurdles arise, the speed of biomedical innovation must inevitably slow down. On top of this, reliable IP framework conditions are being challenged.

The Swiss Biotech Association has established a tight network of partners in Switzerland and abroad who are aligned around the shared objective to optimize global framework conditions for biotech startups and SMEs focusing on R&D (see partner organizations on p. 26).

In 2022, we focus on:

- Re-establishing Switzerland's full association with the Horizon Europe R&D program
- Emphasizing the need for high quality animal testing facilities for biotech companies in Switzerland, highlighting the risks associated with outsourcing such testing to other countries
- Opposing the proposed TRIPS (Trade Related Aspects of Intellectual Property Rights) waiver, which aims at weakening the international IP framework and thereby risks undermining biomedical innovation

	CANEDICIS C CC	00 0 0 0 0 0 0
	600000 1900 C 1 /0	00 0 0 0 0 0 0
2 Van - Digenservens	00000 0000 0 0 0	00 10 0 0 1 0
0/02/0 X010 /00 79-20/030/07	7000100 0010 1 1/ 0	00 1 1 0 0 0 0
and the second second		
All and to an on no an	1000001 001 000 0	00 0 0 0 0 0 0
a state of a state of a		00 0 0 0 0
	THURSDA GOO AND	
	NO FEED ALL PROPERTY AND THE	

Talent and finance

The second pillar in our mission focuses on supporting Swiss-based biotech companies in accessing international talents, financial funding, and access to new technologies. When biotech companies have access to these critical resources, they can benefit from the competitive framework conditions that Switzerland offers. In 2022, the Swiss Biotech Association aims to support this mission objective by:

- Building a talent pool platform for the Swiss biotech industry and its partners. The 'Swiss Biotech Orbit' is designed to attract and retain biotech talents and facilitate their matching with open job opportunities
- Further expanding professional education and training through the Swiss Biotech Association Academy platform
- Promoting and expanding the use of our non-public Swiss Biotech Ventures platform to facilitate matching of biotech companies, investors, and pharma partners
- Promoting the SPARKS segment of the Swiss Stock Exchange to facilitate access to capital markets for Swiss and European biotech SMEs
- Expanding the list of partnerships which offer business solutions that reduce operating costs for our members



Networking and information exchange

This year, the Swiss Biotech Day, our flagship networking event, will be held over the course of two days in Basel on May 2-3, 2022. As part of our strategy of constantly expanding our event and trading partner network, we have expanded our co-promotion agreements with life science conferences around the globe, providing members with attractive discounts and presentation opportunities.

In 2022, we plan to:

- Strengthen the Swiss Biotech Day with additional networking opportunities for biotech CEOs, investors and multi-national pharma companies
- Continue to expand the Swiss R&D biotech CEO meeting platform
- Collaborate with the Swiss Private Equity & Corporate Finance Association and Sachs Associates to exploit synergies with biotech investor meetings
- Collaborate with the Swiss Academy of Technical Sciences (SATW) in promoting the potential of industrial biotech and sustainable manufacturing
- Kick off the 'Global Village' platform to invite international delegations to specifically strengthen the bilateral relationship in life sciences between the guest countries and Switzerland



Promotion and awareness

The Swiss biotech industry has demonstrated its innovation power in providing solutions to address the global Covid pandemic. The Swiss biotech hub is recognized as an attractive partner for R&D collaborations, international talents, academic institutions, and industry partners. International investors value the investment opportunities Switzerland can offer in this field.

Nevertheless, the pricing of, and access to therapeutic opportunities continue to be hotly debated. That is why the association highlights the importance of a fair reimbursement for innovators and their investors who bear the risks associated with drug R&D. Such reimbursement is vital to ensure that investors and biotech entrepreneurs alike continue to engage and invest in the development of innovative medical treatment options.

We will continue to effectively present the strength and diversity of the more than 1,000 biotech companies that comprise the Swiss biotech sector. The Swiss Biotech Directory shows that Switzerland has established a very densely populated and highly diversified biotech hub covering all aspects of biotechnology and with a strong international profile.


To support this, in 2022, we will:

- Publish the digital and print edition of the Swiss Biotech Directory
- Publish the Swiss Biotech Report 2022, highlighting the key sources of Swiss innovation
- Present the Swiss Biotech Success Story Award to the 2022 laureates and nominate the 2023 laureates
- Expand the partner network to support industry promotion and raise awareness of Swiss biotech accomplishments and needs



Clear focus on what really matters

Aligning our objectives to our mission statement ensures a clear focus on what really matters. However, the priorities may vary and depend on the role and point of view of each stakeholder.



We see the strong growth of our membership base as an expression of trust and a confirmation that we are on the right track.

We encourage you to continue to engage in an active dialogue with us to jointly shape the future of our industry and its framework, and thereby keep Swiss biotech successful and competitive internationally.

Yours faithfully,

Michael Altorfer CEO



Swiss Biotech Association Stauffacherstrasse 16 8004 Zürich Switzerland

T: +41 44 455 56 78

info@swissbiotech.org swissbiotech.org